Novartis gets approval to sell Kymriah in Japan for $306,000

55

A Japanese government panel approved on Wednesday a price of 33.5 million yen ($305,800) for Novartis’ cancer treatment Kymriah, allowing the Swiss drugmaker to press ahead with a campaign to kick-start sluggish sales of the treatment.

http://feeds.reuters.com/~r/reuters/healthNews/~3/TewMaLMXPRs/novartis-gets-approval-to-sell-kymriah-in-japan-for-306000-idUSKCN1SL057